Peptide inhibitors of dengue virus and West Nile virus infectivity

<p>Abstract</p> <p>Viral fusion proteins mediate cell entry by undergoing a series of conformational changes that result in virion-target cell membrane fusion. Class I viral fusion proteins, such as those encoded by influenza virus and human immunodeficiency virus (HIV), contain tw...

Full description

Bibliographic Details
Main Authors: Garry Robert F, Hrobowski Yancey M, Michael Scott F
Format: Article
Language:English
Published: BMC 2005-06-01
Series:Virology Journal
Online Access:http://www.virologyj.com/content/2/1/49
_version_ 1818137304784437248
author Garry Robert F
Hrobowski Yancey M
Michael Scott F
author_facet Garry Robert F
Hrobowski Yancey M
Michael Scott F
author_sort Garry Robert F
collection DOAJ
description <p>Abstract</p> <p>Viral fusion proteins mediate cell entry by undergoing a series of conformational changes that result in virion-target cell membrane fusion. Class I viral fusion proteins, such as those encoded by influenza virus and human immunodeficiency virus (HIV), contain two prominent alpha helices. Peptides that mimic portions of these alpha helices inhibit structural rearrangements of the fusion proteins and prevent viral infection. The envelope glycoprotein (E) of flaviviruses, such as West Nile virus (WNV) and dengue virus (DENV), are class II viral fusion proteins comprised predominantly of beta sheets. We used a physio-chemical algorithm, the Wimley-White interfacial hydrophobicity scale (WWIHS) <abbrgrp><abbr bid="B1">1</abbr></abbrgrp> in combination with known structural data to identify potential peptide inhibitors of WNV and DENV infectivity that target the viral E protein. Viral inhibition assays confirm that several of these peptides specifically interfere with target virus entry with 50% inhibitory concentration (IC50) in the 10 μM range. Inhibitory peptides similar in sequence to domains with a significant WWIHS scores, including domain II (IIb), and the stem domain, were detected. DN59, a peptide corresponding to the stem domain of DENV, inhibited infection by DENV (>99% inhibition of plaque formation at a concentrations of <25 μM) and cross-inhibition of WNV fusion/infectivity (>99% inhibition at <25 μM) was also demonstrated with DN59. However, a potent WNV inhibitory peptide, WN83, which corresponds to WNV E domain IIb, did not inhibit infectivity by DENV. Additional results suggest that these inhibitory peptides are noncytotoxic and act in a sequence specific manner. The inhibitory peptides identified here can serve as lead compounds for the development of peptide drugs for flavivirus infection.</p>
first_indexed 2024-12-11T09:54:11Z
format Article
id doaj.art-f98692690eab4d9d85996f17b6eb85d7
institution Directory Open Access Journal
issn 1743-422X
language English
last_indexed 2024-12-11T09:54:11Z
publishDate 2005-06-01
publisher BMC
record_format Article
series Virology Journal
spelling doaj.art-f98692690eab4d9d85996f17b6eb85d72022-12-22T01:12:18ZengBMCVirology Journal1743-422X2005-06-01214910.1186/1743-422X-2-49Peptide inhibitors of dengue virus and West Nile virus infectivityGarry Robert FHrobowski Yancey MMichael Scott F<p>Abstract</p> <p>Viral fusion proteins mediate cell entry by undergoing a series of conformational changes that result in virion-target cell membrane fusion. Class I viral fusion proteins, such as those encoded by influenza virus and human immunodeficiency virus (HIV), contain two prominent alpha helices. Peptides that mimic portions of these alpha helices inhibit structural rearrangements of the fusion proteins and prevent viral infection. The envelope glycoprotein (E) of flaviviruses, such as West Nile virus (WNV) and dengue virus (DENV), are class II viral fusion proteins comprised predominantly of beta sheets. We used a physio-chemical algorithm, the Wimley-White interfacial hydrophobicity scale (WWIHS) <abbrgrp><abbr bid="B1">1</abbr></abbrgrp> in combination with known structural data to identify potential peptide inhibitors of WNV and DENV infectivity that target the viral E protein. Viral inhibition assays confirm that several of these peptides specifically interfere with target virus entry with 50% inhibitory concentration (IC50) in the 10 μM range. Inhibitory peptides similar in sequence to domains with a significant WWIHS scores, including domain II (IIb), and the stem domain, were detected. DN59, a peptide corresponding to the stem domain of DENV, inhibited infection by DENV (>99% inhibition of plaque formation at a concentrations of <25 μM) and cross-inhibition of WNV fusion/infectivity (>99% inhibition at <25 μM) was also demonstrated with DN59. However, a potent WNV inhibitory peptide, WN83, which corresponds to WNV E domain IIb, did not inhibit infectivity by DENV. Additional results suggest that these inhibitory peptides are noncytotoxic and act in a sequence specific manner. The inhibitory peptides identified here can serve as lead compounds for the development of peptide drugs for flavivirus infection.</p>http://www.virologyj.com/content/2/1/49
spellingShingle Garry Robert F
Hrobowski Yancey M
Michael Scott F
Peptide inhibitors of dengue virus and West Nile virus infectivity
Virology Journal
title Peptide inhibitors of dengue virus and West Nile virus infectivity
title_full Peptide inhibitors of dengue virus and West Nile virus infectivity
title_fullStr Peptide inhibitors of dengue virus and West Nile virus infectivity
title_full_unstemmed Peptide inhibitors of dengue virus and West Nile virus infectivity
title_short Peptide inhibitors of dengue virus and West Nile virus infectivity
title_sort peptide inhibitors of dengue virus and west nile virus infectivity
url http://www.virologyj.com/content/2/1/49
work_keys_str_mv AT garryrobertf peptideinhibitorsofdenguevirusandwestnilevirusinfectivity
AT hrobowskiyanceym peptideinhibitorsofdenguevirusandwestnilevirusinfectivity
AT michaelscottf peptideinhibitorsofdenguevirusandwestnilevirusinfectivity